Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $35.0 million.

  • Gain Therapeutics' Shares Outstanding (Diluted Average) rose 3191.01% to $35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year increase of 3191.01%. This contributed to the annual value of $22.9 million for FY2024, which is 7585.72% up from last year.
  • As of Q3 2025, Gain Therapeutics' Shares Outstanding (Diluted Average) stood at $35.0 million, which was up 3191.01% from $30.3 million recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Shares Outstanding (Diluted Average) peaked at $35.0 million during Q3 2025, and registered a low of $4.9 million during Q1 2021.
  • In the last 5 years, Gain Therapeutics' Shares Outstanding (Diluted Average) had a median value of $12.4 million in 2023 and averaged $16.7 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 49928.7% in 2021, then increased by 5.58% in 2022.
  • Gain Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $10.2 million in 2021, then grew by 16.9% to $11.9 million in 2022, then grew by 9.49% to $13.0 million in 2023, then soared by 75.86% to $22.9 million in 2024, then surged by 52.95% to $35.0 million in 2025.
  • Its last three reported values are $35.0 million in Q3 2025, $30.3 million for Q2 2025, and $28.7 million during Q1 2025.